| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
21,293 |
19,031 |
$472K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
5,857 |
5,128 |
$154K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
3,435 |
2,996 |
$119K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
1,910 |
1,599 |
$102K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
1,509 |
1,294 |
$56K |
| 20553 |
|
1,113 |
957 |
$25K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
404 |
366 |
$23K |
| 90837 |
Psychotherapy, 53 minutes with patient |
332 |
196 |
$22K |
| 80364 |
|
853 |
823 |
$15K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
866 |
751 |
$11K |
| 93040 |
|
1,502 |
1,292 |
$11K |
| 64483 |
|
176 |
160 |
$11K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
296 |
89 |
$6K |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
834 |
740 |
$5K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
533 |
474 |
$4K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
221 |
69 |
$3K |
| 64484 |
|
58 |
54 |
$3K |
| 94761 |
|
1,424 |
1,219 |
$2K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
162 |
144 |
$1K |
| 96132 |
|
42 |
40 |
$1K |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
2,636 |
2,232 |
$842.77 |
| 95886 |
|
25 |
25 |
$663.25 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,413 |
1,211 |
$547.86 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
136 |
120 |
$187.11 |
| 96138 |
|
39 |
37 |
$147.00 |
| 99442 |
|
18 |
12 |
$95.69 |
| G0283 |
Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care |
201 |
76 |
$55.19 |
| A4550 |
Surgical trays |
1,564 |
1,356 |
$16.30 |
| G9903 |
Patient screened for tobacco use and identified as a tobacco non-user |
11,228 |
9,824 |
$0.00 |
| G9906 |
Patient identified as a tobacco user received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling and/or pharmacotherapy) |
1,660 |
1,394 |
$0.00 |
| G8950 |
Elevated or hypertensive blood pressure reading documented, and the indicated follow-up is documented |
8,775 |
7,909 |
$0.00 |
| G9902 |
Patient screened for tobacco use and identified as a tobacco user |
7,714 |
6,950 |
$0.00 |
| G8420 |
Bmi is documented within normal parameters and no follow-up plan is required |
4,534 |
4,015 |
$0.00 |
| 1036F |
|
6,213 |
5,676 |
$0.00 |
| G8418 |
Bmi is documented below normal parameters and a follow-up plan is documented |
37 |
32 |
$0.00 |
| G9367 |
At least two orders for high-risk medications from the same drug class |
64 |
58 |
$0.00 |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
11,863 |
10,352 |
$0.00 |
| 4004F |
|
8,812 |
7,828 |
$0.00 |
| G8730 |
Pain assessment documented as positive using a standardized tool and a follow-up plan is documented |
4,475 |
3,596 |
$0.00 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
20,177 |
17,782 |
$0.00 |
| 3288F |
|
1,029 |
900 |
$0.00 |
| G9562 |
Patients who had a follow-up evaluation conducted at least every three months during opioid therapy |
3,072 |
2,509 |
$0.00 |
| 1124F |
|
1,522 |
1,306 |
$0.00 |
| G8783 |
Normal blood pressure reading documented, follow-up not required |
5,571 |
5,021 |
$0.00 |
| G9584 |
Patient evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient interviewed at least once during opioid therapy |
2,438 |
1,987 |
$0.00 |
| 1100F |
|
128 |
122 |
$0.00 |
| G9622 |
Patient not identified as an unhealthy alcohol user when screened for unhealthy alcohol use using a systematic screening method |
355 |
294 |
$0.00 |
| G9578 |
Documentation of signed opioid treatment agreement at least once during opioid therapy |
720 |
594 |
$0.00 |